Evidence map›Paper›PMID 27275096›Full record

ArticleWorld journal of gastroenterology2016

Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.

Jun Qian, Elsie Oppermann, Andreas Tran, Ulli Imlau, Kun Qian, Thomas Josef Vogl

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Histochemistry for Molecular Imaging in Nanomedicine.International journal of molecular sciences · 2024
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Jun QianJun Qian, Kun Qian, Department of Radiology, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Elsie OppermannJun Qian, Kun Qian, Department of Radiology, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Andreas TranJun Qian, Kun Qian, Department of Radiology, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Ulli ImlauJun Qian, Kun Qian, Department of Radiology, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Kun QianJun Qian, Kun Qian, Department of Radiology, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Thomas Josef VoglJun Qian, Kun Qian, Department of Radiology, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Union Hospital · USHuazhong University of Science and Technology · CNGoethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo compare the effect of transarterial chemoembolization (TACE) plus GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro, integrin-inhibitor) loaded nanoparticles with TACE alone or TACE + GRGDSP in a rat model of liver tumor.

methodsMorris hepatoma 3924A tumors were implanted in the livers of 30 ACI rats. The ACI rats were divided randomly into three groups (10 animals each). Tumor volume before treatment (V1) was examined by magnetic resonance imaging (MRI), and then, after laparotomy and placement of a PE-10 catheter into the hepatic artery, the following interventional protocols were performed: TACE (mitomycin C + lipiodol + degradable starch microspheres) + GRGDSP loaded nanoparticles for group A; TACE + GRGDSP for group B (control group 1); TACE alone for group C (control group 2). Tumor volume (V2) was assessed by MRI and the mean ratio of the post-treatment to pretreatment tumor volumes (V2/V1) was calculated. Immunohistochemical analysis was performed to assess the quantification of matrix metalloprotein 9 (MMP-9) and vascular endothelial growth factor (VEGF) positive tumor cells in each treatment group.

resultsThe mean tumor growth ratios (V2/V1) were 1.3649 ± 0.1194 in group A, 2.0770 ± 0.1595 in group B, and 3.2148 ± 0.1075 in group C. Compared with groups B and C, group A showed a significant reduction in tumor volume. Lower expression of MMP-9 and VEGF in hepatocellular carcinoma was observed in group A than in groups B and C. The angiogenesis of tumor was evaluated using anti-VEGF antibodies, and the metastasis of tumor was assessed using anti-MMP-9 antibody. MMP-9 and VEGF were expressed in all specimens. The immunoexpression of these proteins was confirmed by the presence of red cytoplasmic staining in tumor cells. Lower expression of MMP-9 and VEGF in hepatocellular carcinoma was observed in group A than in groups B and C.

conclusionTransarterial administration of integrin inhibitor loaded nanoparticles combined with TACE evidently retards tumor growth and intrahepatic metastases compared with TACE alone or TACE plus integrin inhibitor in an animal model of hepatocellular carcinoma.

Indexed as

NanoparticlesAnimalsAntineoplastic AgentsCarcinoma, HepatocellularCell ProliferationChemoembolization, TherapeuticEthiodized OilHepatic ArteryImmunohistochemistryInjections, Intra-ArterialIntegrinsLiver Neoplasms, ExperimentalMagnetic Resonance ImagingMaleMatrix Metalloproteinase 9NanomedicineAntineoplastic AgentsEthiodized Oilglycyl-arginyl-glycyl-aspartyl-seryl-prolineIntegrinsMatrix Metalloproteinase 9Mmp9 protein, ratOligopeptidesVascular Endothelial Growth Factor Avascular endothelial growth factor A, ratACI ratsHepatocellular carcinomaIntegrin inhibitorMatrix metalloprotein 9NanoparticlesTransarterial chemoembolizationVascular endothelial growth factor

Identifiers

PMID27275096
PMCPMC4886379
OpenAlexW2410541359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.